Merck & Co. Inc (6MK BE) stock market data APIs
€70.6718
0.59(0.8%)
as of July 17, 2025
Try our APIs with
free plan!
Merck & Co. Inc Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for 6MK.BE.
Prev. Close
70.6718
Open
71.2582
High
71.967
Low
70.6718
52 wk Range
64.8498-115.4747
Market Cap
162 424 M
Dividends (Yield)
0.0234
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Merck & Co. Inc data using free add-ons & libraries
Get Merck & Co. Inc Fundamental Data
Merck & Co. Inc Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Merck & Co. Inc News
New
Eli Lilly vs. Merck: Which Drug Giant Appears Better Poised Today?
Both Eli Lilly LLY and Merck MRK are major players in the U.S. pharmaceutical industry, developing and commercializing therapies across oncology, immunology, and diabetes and cardiovascular areas. Whi...
Grignard Reagents Global Market Forecast Report 2025-2030 | Emergence of Green Chemistry and Sustainable Practices, & Rising Demand in Asia-Pacific Driving Multi-Billion Opportunities
Company Logo The global Grignard reagents market is projected to grow from USD 5.07 billion in 2025 to USD 6.67 billion by 2030, at a CAGR of 5.6%. Aryl Grignard reagents hold a significant share due...
Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth?
Recursion Pharmaceuticals RXRX is strategically leveraging its AI-powered drug discovery platform through multiple high-value collaborations, positioning itself for long-term growth and sustainability...
Mizuho Maintains an Overweight Rating on Vaxcyte (PCVX)
Vaxcyte, Inc. (NASDAQ:PCVX) is one of the best oversold NASDAQ stocks to buy now. On June 20, Mizuho analyst Salim Syed commented on Vaxcyte, Inc. (NASDAQ:PCVX), on which the firm maintained an Outper...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
